
Eli Lilly CEO David A. Ricks has unveiled one of the most ambitious expansions in the pharmaceutical titan's history: a $6 billion manufacturing facility in Greenbrier South, Huntsville, Alabama, dedicated to producing the next generation of obesity medicines.
The plant will focus primarily on orforglipron, Lilly's highly anticipated once-daily oral obesity treatment, which analysts say could reshape a pharmaceutical market currently dominated by injectables.